Methyltestosterone

Oral
Male hypogonadism

Oral
Metastatic breast carcinoma in postmenopausal women

Men with breast cancer, known or suspected prostate cancer. Pregnancy.

Patient with CV disease, benign prostatic hyperplasia, chronic lung disease; obesity. Renal and hepatic impairment. Lactation.

Significant: Peliosis hepatis, hepatic neoplasms, hepatocellular carcinoma, cholestatic hepatitis, jaundice, MI, stroke, DVT, pulmonary embolism, polycythaemia, oligospermia, reduced ejaculatory volume, priapism, benign prostatic hypertrophy, sleep apnoea.
Blood and lymphatic system disorders: Clotting factors suppression.
Endocrine disorders: Hirsutism.
Gastrointestinal disorders: Nausea, vomiting.
Immune system disorders: Anaphylactic reactions.
Investigations: Change in libido.
Metabolism and nutrition disorders: Hypercholesterolaemia.
Nervous system disorders: Headache, paraesthesia.
Psychiatric disorders: Depression, anxiety.
Reproductive system and breast disorders: Amenorrhoea, impotence, mastalgia, testicular atrophy.
Skin and subcutaneous tissue disorders: Acne vulgaris, androgenetic alopecia.

PO: X

Monitor LFTs, lipid profile, haemoglobin and haematocrit (at 3-6 months and annually thereafter); urine, and serum Ca. Monitor serum glucose in diabetic patients; prostate specific antigen if clinically indicated. Assess for signs of virilisation in women. Perform radiologic examination of the wrist and hand for prepubertal patients every 6 months.

Enhanced effect of anticoagulants and hypoglycaemic agent. Increased hepatotoxicity of ciclosporin. Increased plasma concentrations of oxyphenbutazone.

May decrease thyroxine-binding globulin concentrations.

Description: Methyltestosterone is a synthetic anabolic steroid hormone which promotes growth and development of male sex organs. It also aids in the maintenance of secondary sex characteristics in androgen-deficient men.
Pharmacokinetics:
Absorption: Absorbed from the gastrointestinal tract.
Distribution: Plasma protein binding: 98% mainly to sex hormone-binding globulin.
Metabolism: Metabolised in the liver.
Excretion: Mainly via urine (approx 90%); faeces (approx 6%). Elimination half-life: 10-100 minutes.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6010, Methyltestosterone. https://pubchem.ncbi.nlm.nih.gov/compound/Methyltestosterone. Accessed Oct. 27, 2020.

Store between 15-30°C. Protect from light, moisture, and heat.

Androgens & Related Synthetic Drugs / Cancer Hormone Therapy

G03BA02 - methyltestosterone ; Belongs to the class of 3-oxoandrosten (4) derivative androgens used in androgenic hormone preparations.

Anon. Methyltestosterone. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 08/09/2020.

Anon. Methyltestosterone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/09/2020.

Buckingham R (ed). Methyltestosterone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/09/2020.

Methitest Tablets (Amneal Pharmaceuticals of New York LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/09/2020.

Methyltestosterone Capsule (Amneal Pharmaceuticals of New York LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/09/2020.